Shingo Toyama

ORCID: 0000-0003-2646-3014
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Radiation Therapy and Dosimetry
  • Pancreatic and Hepatic Oncology Research
  • Prostate Cancer Diagnosis and Treatment
  • Advanced Radiotherapy Techniques
  • Prostate Cancer Treatment and Research
  • Hepatocellular Carcinoma Treatment and Prognosis
  • Cancer Genomics and Diagnostics
  • Ocular Oncology and Treatments
  • Liver Disease Diagnosis and Treatment
  • Renal cell carcinoma treatment
  • Cholangiocarcinoma and Gallbladder Cancer Studies
  • Organ Transplantation Techniques and Outcomes
  • Gallbladder and Bile Duct Disorders
  • Neuroendocrine Tumor Research Advances
  • Nasolacrimal Duct Obstruction Treatments
  • Cancer Research and Treatments
  • Lung Cancer Diagnosis and Treatment
  • Pericarditis and Cardiac Tamponade
  • Colorectal Cancer Treatments and Studies
  • Atomic and Subatomic Physics Research
  • Radiation Effects and Dosimetry
  • Surgical site infection prevention
  • Cardiovascular and Diving-Related Complications
  • CNS Lymphoma Diagnosis and Treatment
  • Ocular Infections and Treatments

SAGA Heavy Ion Medical Accelerator in Tosu
2014-2024

Tohoku University
2016-2018

Azienda Unità Sanitaria Locale 11 di Empoli
2018

Policlinico S.Orsola-Malpighi
2017

Saga University
2012-2013

National Institute for Physiological Sciences
2013

Background and purposeA multi-institutional observational study (J-CROS1501PR) has been carried out to analyze outcomes of carbon-ion radiotherapy (CIRT) for patients with prostate cancer.Patients methodsData the enrolled in prospective studies following 3 CIRT institutions were analyzed: National Institute Radiological Sciences (NIRS; Chiba, Japan), Gunma University Heavy Ion Medical Center (GHMC; Gunma, Beam Therapy Center, SAGA HIMAT Foundation (HIMAT; Saga, Japan). Endpoints clinical...

10.1016/j.radonc.2016.10.009 article EN cc-by-nc-nd Radiotherapy and Oncology 2016-11-01

The purpose of this study was to evaluate the feasibility a new shortened 3-week treatment schedule carbon ion radiotherapy (CIRT) for prostate cancer. Beginning in May 2010, patients with T1b–T3bN0M0, histologically proven adenocarcinoma were enrolled phase II trial CIRT. Patients received 51.6 GyE 12 fractions over 3 weeks (protocol 1002). primary end point defined as incidence late adverse events that evaluated based on Common Terminology Criteria Adverse Events version 4.0. Biochemical...

10.1038/bjc.2014.191 article EN cc-by-nc-sa British Journal of Cancer 2014-04-10

Abstract Background & Aims Carbon‐ion radiation therapy has shown encouraging results in hepatocellular carcinoma patients single‐centre studies. We evaluated the effectiveness and safety of short‐course carbon‐ion for a multicentre study conducted by Japan Carbon Ion Radiation Oncology Study Group. Methods Consecutive who were treated with four or fewer fractions at Japanese institutions between April 2005 November 2014 analysed retrospectively. The primary outcome was overall survival;...

10.1111/liv.13969 article EN Liver International 2018-09-22

// Goro Kasuya 1 , Kazuki Terashima 2 Kei Shibuya 3 Shingo Toyama 4 Daniel K. Ebner 5 Hiroshi Tsuji Tomoaki Okimoto Tatsuya Ohno Yoshiyuki Shioyama 6 Takashi Nakano Tadashi Kamada and the Japan Carbon-Ion Radiation Oncology Study Group QST Hospital (Former of National Institute Radiological Sciences), Institutes for Quantum Science Technology, Chiba, Department Radiology, Hyogo Ion Beam Medical Center, Tatsuno, Gunma University Heavy Maebashi, Therapy SAGA-HIMAT Foundation, Tosu, Harvard TH...

10.18632/oncotarget.27028 article EN Oncotarget 2019-07-08

Abstract Reports on the therapeutic efficacy and safety of carbon‐ion radiotherapy (C‐ion RT) for oligometastatic liver disease are limited, with insufficient evidence. This study aimed to evaluate clinical outcomes C‐ion RT at all Japanese facilities using nationwide cohort data. We reviewed medical records obtain registry data between May 2016 June 2020. Patients (1) as confirmed by histological or diagnostic imaging, (2) ≤3 synchronous metastases time treatment, (3) without active...

10.1111/cas.15871 article EN cc-by-nc Cancer Science 2023-06-30

症例は66歳の男性で,腹痛・血便などを主訴に来院.腸管壊死を伴わない上腸間膜動脈血栓症と診断して保存的加療を試みたものの,第2病日に腹部症状が増悪したため緊急手術を施行し,壊死小腸約50cmを部分切除するとともにsecond-look operationの方針で断端は小腸瘻として腹壁外に挙上した.術後第12病日に小腸を約70cm追加切除し,小腸瘻を閉鎖した.再手術後,経口摂取に誘発される腹痛と下痢を繰り返し,CT・蛋白漏出シンチグラムなどの精査にて虚血性小腸炎に合併した蛋白漏出性胃腸症と診断した.3度目の手術では詳細な観察のため,腹腔鏡を使用し,前回吻合部の口側約50cmにわたる小腸腸管壁の肥厚を認めた.小腸大量切除を回避するためsecond-look operationを企図したが,蛋白漏出性胃腸症の合併から結果的に3度の手術と長期入院を要した1例を経験したので,考察とともに報告する.

10.3919/jjsa.76.1918 article JA Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association) 2015-01-01

症例は73歳女性.胸部CTにて右肺S3に充実性陰影を伴うスリガラス陰影(mixed GGO)を認めた.4ヵ月間の経過観察で変化がなかったため,胸腔鏡下生検のため入院となった.手術直前にフックワイヤーを用いたCTガイド下マーキングを施行したところ,突然意識消失を来した.CTにて上行大動脈内と右大脳半球の脳溝に空気の存在を確認,まもなく左片麻痺と全身痙攣を発症,ただちに脳梗塞急性期の治療を行った.全身状態の落ち着いた4週間後に胸腔鏡下右肺部分切除術を施行.発症後8ヵ月の現在,左半身の脱力は残存している.稀に重篤な空気塞栓症が生じるため,フックワイヤーによるマーキングの適応については慎重に決定すべきである.

10.2995/jacsurg.28.966 article EN The Journal of the Japanese Association for Chest Surgery 2014-01-01

TPS504 Background: Despite recent advances in chemotherapy and radiotherapy, prognosis of unresectable locally advanced pancreatic cancer (LAPC) patients remains poor. To improve the outcome, a phase I/II clinical trial carbon-ion radiotherapy (CIRT) with concurrent gemcitabine for LAPC was started National Institute Radiological Sciences Japan.When compared to photon beams, carbon ion beams offer improved dose distribution, enabling us concentrate sufficient within target volume while...

10.1200/jco.2015.33.3_suppl.tps504 article EN Journal of Clinical Oncology 2015-01-20

671 Background: Carbon-ion radiotherapy (C-ion RT) has the potential advantages in terms of improved dose localization and enhanced biological effectiveness compared to conventional or proton therapy. C-ion RT is expected contribute prolongation survival patients with pancreatic ductal adenocarcinoma (PDAC). We started for cancer at SAGA HIMAT since April 2014. The aim this study evaluate long-term clinical results locally advanced PDAC. Methods: From 2014 March 2018, 144 were treated...

10.1200/jco.2020.38.4_suppl.671 article EN Journal of Clinical Oncology 2020-02-01
Coming Soon ...